The goal of Project IVD102 is to develop a detection and identification system for corona viruses including the 2019-nCoV Acute Respiratory Disease and respective influence viruses as a point-of-care device allowing a sample-to-answer operation. This aim will be addresses with a lab-on-a-chip approach consisting of the “Chip” as a consumable and the instrument to run and control the chip. Operation of the system will work as following: After sample introduction on the chip and insertion in the respective instrument, the sequence carried out in the lab-on-a-chip system without any further manual interaction comprise: Sample enrichment, lysis, target concentration, multiplexed quantitative amplification and detection.
The project will deliver a point-of-care diagnostic platform for the simultaneous detection of the 2019-nCoV and further RNA viruses causing similar symptoms, without the need for equipped laboratory infrastructures or trained users, and a rapid turnaround time of 90 minutes from sample-to-answer allowing for 150 parallel amplifications. The system will be validated and will reach TRL 9 at the project end.

Project IVD103 has developed a portable CRISPR-based kit for molecular diagnostics of COVID-19 (powered by novel/enhanced Cas enzymes). The company has been developing its technology as a platform, being capable of easily readapting to new targets. Recently, since the emergence of COVID-19 the team has developed a CRISPR complex (Cas enzyme + COVID-19 complementary RNA Guide), and validated it’s performance using synthetic targets and a synthetic sample of sputum (as a proof of principle of real patient sample). Caspr’s lateral flow-based test enables detection in less than 60 minutes, with minimal sample preparation.
Previously, company has been working with Hospitals & Labs in validations concerning detection limits(reaching attomolar levels) and performance of targets corresponding to different Infectious Diseases (DENV, HANTAV, ZIKA, amongst others).
Project is looking for opportunities of working with global health institutions and governments in order to further validate the aforementioned portable kit with real samples and try to scale it to production phase as soon as possible. Initial connections have been established with officials that correspond to the government of Philippines and China.
Current detection tests of COVID-19 show drawbacks when providing people and professionals with the relevant and precise information in time critical conditions. Decentralized testing is only based on symptoms assessment (temperature measurement, CT scans), thus leading to a high rate of false negatives. This is particularly relevant taking into account that incubation period has been estimated to be of up to 24 days. Hence COVID-19 spreading might occur before symptoms appear. Molecular tests (qPCR) are limited to lab settings, taking days YO PONDRIA SEVERAL HOURS ACA for results to be available and being performed in a centralized manner. Our fast, precise & portable Molecular detection solution could be crucial in better controlling and managing COVID-19.

Broad-range molecular diagnostics for identification of 1300 deadliest and unidentified pathogens

A Tufts University spinout startup develops a high-performing, efficient technology platform for cancer diagnostics. The core technology leverages the power of atomic force microscopy cell surface scanning and machine learning modeling to derive a robust diagnostic score. A urine-based bladder cancer monitoring is the beachhead application for our technology which we have gained 94% accuracy from a multicenter proof-of-concept study. We provide a laboratory-developed test (LDT) for patient-oriented urologists network and hospitals by partnering with a CLIA-compliant lab. We have gained high interest from urological oncologists and key opinion leaders from the U.S., and we are interested in bringing this solution to replace invasive cystoscopies for Chinese patients as well.

Multi-omics diagnostic platform: The team, together with Dr. Daniel Daniel and Dr. Zhang Zhen of Johns Hopkins School of Medicine, build a tool component that can detect multiple types of cancer early by adopting Multiomics/AI methods. Multiomics is regarded as one of the most effective tools for cancer diagnosis in the future. It integrates genomics, epigenomics, transcriptomics and proteomics data, and can conduct a comprehensive analysis of cell dynamics. The company has set up R&D at Hangzhou Pharmaceutical Port and cooperated with Fudan University Red House Hospital.

Project IVD107 is based on a US patent to screen for breast cancer through newly discovered cancer markers in the blood. This discovery has been verified by more than 500 columns in the United States. Not only the results are satisfactory (sensitivity and specificity are 86.2% and 100%, respectively), but also the early stage of breast cancer (before stage 0 formation) has obvious expression. Not only can it be used as an early screening for breast cancer, it can also be used as a detection method for breast cancer treatment. It is believed that this will be a major breakthrough in breast cancer detection, especially in the early screening of breast cancer.
The project plans to land in China to produce ELISA kits and intermediate products-antigen antibodies for early detection of breast cancer.

CoronaVirus Treament & Diagnostics / Obesity Treatment / Cancer Treatment / Diabetic Foot Treatment/ Dementia Treatment

Company is a leader in liquid biopsy. Its InXXX® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, XXVisionXXX™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on XXVisionXXX™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK.

By analyzing the blood of patients, the goal of detecting Alzheimer’s disease 15-20 years in advance is achieved, helping patients get treatment as soon as possible

Project IVD111 is offering “game-changing” technology to address women who needlessly die due to the lack of a simple, reliable and cost-effective means to screen for cervical disease. Project brings to the marketplace ixxx™, a patented sample self-collection device coupled with Cerxxx™ Point-of-Care and LAB systems that detects persistent high-risk HPV infections (the cause of cervical disease) as well as evidence and prognostic risk of precancerous lesions. Initially targeting the unmet needs of women in the developing world markets, Cerxxx offers convenience to women in the developed world markets as well. Similar in approach to at-home colon cancer screening, (e.g. Coloxxx®), ixxx & Cerxxx systems support self-sampling and near instant results provided by pharmacy, clinic or MD office.

Development of a new, cost-effective, accurate targeted DNA tests (digital PCR) to monitor infectious diseases, also relevant to COVID-19

in vitro cancer diagnostic reagents

Project IVD115 invented a device to copy biomolcules. We take DNA as input and generate microarrays in terms of DNA, RNA and proteins. If we take e.g. cDNA of a virus, we can with a blood sample of a survivor identify the potential vaccine candidate molecules. Same technqieu can be used to see if a vaccine yields correct folded proteins (and has therefore high potential to raise immunity) and after vaccination can be used to control if the vaccinated persons develop the same antibody pattern as an infected one. So 3 levels of defence for pandemics. Apart from that the platform can be used to measure antibody titers against known diseases (so to say a kind of immunity control) and also for allergies. Basically it can be used for blood antibody monitoring.

Project REH101 employs its proprietary excipient library, BioXxxx®, to unlock new clinical benefits of already-approved treatments in the fields of diabetes and metabolism

Project REH101 is committed to solving the huge clinical problem of heart failure rehospitalization. The company uses remote monitoring and AI algorithms to provide doctors and patients with the best diagnostic basis and medication control, effectively reducing the risk of heart failure patients with relapse and greatly reducing the frequency of hospitalization.

Project REH104 develops innovative treatments for metabolic disorders, including type 2 diabetes and NASH. With our partner Sumitomo Dainippon Pharma, we are conducting a Phase 3 program for Imeglimin for type 2 diabetes in Japan. Roivant Sciences is responsible for Imeglimin’s development and commercialization outside of Sumitomo Dainippon Pharma’s territories, including the US and Europe. PXL770, a direct adenosine monophosphate-activated protein kinase activator, is in Phase 2a for NASH and has the potential to treat additional metabolic diseases. PXL065, a mitochondrial pyruvate carrier inhibitor, is in Phase 1 for NASH. Poxel also has earlier-stage programs for metabolic, specialty and rare diseases.”

Project REH105 is Korean biopharmaceutical company focused on the discovery, development and commercialization of innovative global therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers. Curacle’s research efforts are focused on the development of therapeutics inhibiting endothelial dysfunction by tackling multiple mediators including VEGF, Ang-2, bradykinin and so on and maintain vascular homeostasis which is one of the most essential elements in controlling diseases and aging.

Project REH106 provides a patented and clinically validated breath analytics test for the early detection of lung cancer. The Hawkeye test leverages a multi-gene differential expression of RNA from exhaled breath condensate to produce an actionable YES/NO answer.Target applications include: 1) early detection of lung cancer (when it can be treated most effectively), 2) patient stratification for lung health screening, 3) confirmatory lung testing after indeterminate nodules are discovered incidentally or by chest scans (LDCT), and 4) patient monitoring after treatment for the detection of minimal residual disease (MRD).

Project focuses on drugs for anemia & hematological disorders in humans and animals. The company is applying its research, technology and knowledge base for developing and marketing a Canine Anemia drug, produced through its patented, platform technology, EAF PEGylation of Hemoglobin. HEMOMED also possess tremendous data on the efficacy of Quercetin as anti-oxidant and plans to provide a therapeutic formulation to SCD patients through medical nutrition route. Incorporated since 2013, The group is proud to bring its expertise and the passion to commercialize novel products for unmet medical needs which build value for its stakeholders.

At its core, Project REH108 is a speech and language company, specializing in identifying disease and human condition through speech. The technology is patent protected, with three issued US patents and three additional patents pending in the US and internationally. On the cutting edge of a major medical breakthrough to reduce costs, expand telehealth and remote medical services, provide screening for a range of diseases and thus enabling organizations to improve quality of life.

A psychology and engineering project, which aims to become a support company in systems analysis and signals in electrophysiology, dedicated to the study of CNS electrophysiology in magnetoencephalography as a working tool in CNS plasticity. Hybrid between psychology and telecommunications engineering building a project on the psychophysiology of neural networks.

Project WER101 provides an integrated medical IoT platform composed of the world’s most comprehensive vital sign wearable monitor, edge computing, and advanced cloud health data analytics. The company provides its Platform as a Service to over 80 Commercial customers, in both US and China, with $1M revenue in 2019. Examples include Mercy Hospital, Shanghai Public Health Clinical Center, UCSF, and Stanford.Its Band-Aid sized medical-grade monitor is the only device in the world that can perform Blood Pressure, ECG, Respiration, Body Temperature, and Stethoscope functions for wireless patient monitoring. Additional advanced predictive algorithms are under development, in collaboration with world’s top research institutions, for early disease detection and diagnosis. VivaLNK has a very strong med tech team, including PhD’s and MD’s with proven track record in medical device and IoT systems.

Project WER102 develops a special device of detection and decision support system for dialysis patients

The company product portfolio is centered around innovative adhesive composites that can out-compete today’s Standard-of-Care metal implants for fracture fixations. Three product prototypes have already been preclinically validated by surgeons and BMB is now on open for investment that will allow the company to conduct First-in-Man study, CE marking and commercialization. Below is a summary of the USPs that accompanies the products:

– Developed due to the demand from surgeons
– Simple chemistry and scalable compositions
– Viable and personalized surgical method
– Fixation of complex fractures with increased freedom
– Topical, proper and maintained fixation without the need of metal plates. Loadbearing of 20 kg/2cm2
– Non-toxic, non-inflammatory, non-genotoxic

Project ORT102 is focused on developing an optimized, recombinant immunotoxin for treatment of multiple myeloma (MM). Founded by experienced drug developers with an exclusive worldwide Commercial license from the NIH, BEORO pursues a virtual biotech business model for its lead asset BeT101. In-vitro BeT101 selectively kills primary myeloma cells with picomolar potency and in-vivo it has achieved complete cures in two MM xenograft models. BEORO seeks series A investment of €13 mio to develop GMP and analytics processes, perform GLP Tox assessment, and demonstrate clinical proof of concept in a phase 1 study within the next 3 years.

The drug developed by the project is the first oral therapy to repair fractures and keep bones strong. Through preliminary animal experiments and observational studies in more than 1,000 patients outside the United States, the company has proven the efficacy of its drugs in treating fractures, restoring bone tissue, and curing other bone diseases.

AI enabled imaging devices

Project OPH102 is led by Professor Francesca Cordeiro and Mr David Trevor commercialising DARC technology.
DARC technology uses a fluorescently labelled protein to identify stressed, sick and dying nerve cells which can be non-invasively imaged. Combined with a proprietary AI based algorithm, the no. and pattern of DARC spots enables the clinician to identify glaucoma patients 10 years ahead of current standard of care.
If you have a compound for glaucoma or AMD, including gene therapy or you are about to invest in such a company, we can de-risk your clinical development program & investment decision in 2-3 months instead of 2-3 years.

Company is an ophthalmology company backed by European and Chinese investors. It’s proprietary product EyeXXX® is a unique non-invasive device to treat glaucoma with ultrasound. Glaucoma is a chronic serious disease affecting 90 million people worldwide. The standard of care are eyedrops, which often lose their therapeutic effect over time, and surgery which is related to significant risks of complications. EyeXXX® is CE marked, 7,000+ patients treated, 100+ clinical articles and presentations published.

AI enabled imaging devices

Strokes affect 15 million people worldwide, causing hemorrhagic complications, permanent disability, dependency, and death. Project MIE102 is leading the science of objectively diagnosing Large Vessel Occlusion (LVO) ischemic strokes to minimize the delay in care and injury to the brain. We are the leading company focused specifically on the science, development, and commercialization of acoustic-based technologies for the non-invasive detection of neuropathologies. We are passionate about providing objective diagnostics to enhance therapy and time to treatment for patients suffering from ischemic strokes by providing innovative, clinically proven and economically effective diagnostic solutions for physicians and health care providers.

Mammography is a well-established, cost-effective imaging technique for breast cancer detection that has been clinically available worldwide. It is the only screening technology that was proved to reduce mortality and the only one with FDA clearance.Mammography is a well-established, cost-effective imaging technique for breast cancer detection that has been clinically available worldwide. It is the only screening technology that was proved to reduce mortality and the only one with FDA clearance.The company develops a decision support information Hub and Medical Record platform for the Breast Cancer prevention arena, based on:1. XXX module  focused on young women, CESM (Contrast-Enhanced Spectral Mammography):  The module supports radiologist’s decision when the mammography itself cannot show all details (40% to 50% of women below 50 years have dense breasts as well as a significant proportion of women older than 50 years. The overall sensitivity range of mammography is 63%-98% and drops to 30%-58% for dense breast).
The XXX module developed in the SHEBA Hospital over 3 years, by CILAB and MEIRAV and it cost more than $1M.Under the agreement signed on 2020, the company got all the commercialization rights. The system is in use by the SHEBA Hospital – the clinical POC done at the SHEBA with ~170 cases (more 200 are ready complete) with 66% accuracy as stand alone. Together with the physicians, achieved ~90% and decreased the unnecessary biopsies by 30%.2. Mammography Image Comparison Analysis: shows the new and changes between mammograms over time, using our AI and ML Algorithms3. Mobile App: for patient to store and access their medical images records/information, 2nd opinion, unlimited storage for mammography’s images, MRI, ultrasound, biopsy, etc.

Project MIN102 developed a non-invasive device to deliver low-frequency ultrasound (LOTUS) to the kidneys, lungs, and other organs. LOTUS increases local nitric oxide, which acts to both kill the virus and protect the organ. The product has completed initial clinical testing to prevent contrast-induced kidney injury in the cath lab. We have received Breakthrough Device Designation from FDA. We aim to test the same device to prevent kidney injury due to COVID.

The project is led by Professor Francesca Cordeiro and Mr David Trevor commercialising DARC technology.
DARC technology uses a fluorescently labelled protein to identify stressed, sick and dying nerve cells which can be non-invasively imaged. Combined with a proprietary AI based algorithm, the no. and pattern of DARC spots enables the clinician to identify glaucoma patients 10 years ahead of current standard of care.
If you have a compound for glaucoma or AMD, including gene therapy or you are about to invest in such a company, we can de-risk your clinical development program & investment decision in 2-3 months instead of 2-3 years.

The project is committed to solving the huge clinical problem of heart failure rehospitalization. The company uses remote monitoring and AI algorithms to provide doctors and patients with the best diagnostic basis and medication control, effectively reducing the risk of heart failure patients with relapse and greatly reducing the frequency of hospitalization.

Company is an ophthalmology company backed by European and Chinese investors. It’s proprietary product EyeXXX® is a unique non-invasive device to treat glaucoma with ultrasound. Glaucoma is a chronic serious disease affecting 90 million people worldwide. The standard of care are eyedrops, which often lose their therapeutic effect over time, and surgery which is related to significant risks of complications. EyeXXX® is CE marked, 7,000+ patients treated, 100+ clinical articles and presentations published.
China is the company’s core market where access and infrastructure for glaucoma surgery is limited and patients present with advanced disease. EyeXXX® is CFDA registered and revenues are entering since 2018. The company has offices in France and China.

The company product portfolio is centered around innovative adhesive composites that can out-compete today’s Standard-of-Care metal implants for fracture fixations. Three product prototypes have already been preclinically validated by surgeons and BMB is now on open for investment that will allow the company to conduct First-in-Man study, CE marking and commercialization. Below is a summary of the USPs that accompanies the products:

– Developed due to the demand from surgeons
– Simple chemistry and scalable compositions
– Viable and personalized surgical method
– Fixation of complex fractures with increased freedom
– Topical, proper and maintained fixation without the need of metal plates. Loadbearing of 20 kg/2cm2
– Non-toxic, non-inflammatory, non-genotoxic
– Preclinically and Safety evaluated by NAMSA.
– Long-term preclinical study and validation on human cadaver specimens undergoing
Excellent soft-tissue compatibility – STEALTH Technology

The drug developed by the project is the first oral therapy to repair fractures and keep bones strong. Through preliminary animal experiments and observational studies in more than 1,000 patients outside the United States, the company has proven the efficacy of its drugs in treating fractures, restoring bone tissue, and curing other bone diseases.

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ robotic radiation oncology system provides targeted triple-modulated radiotherapy and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, with a single dose. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

Project MIN109 is leading the science of objectively diagnosing Large Vessel Occlusion (LVO) ischemic strokes to minimize the delay in care and injury to the brain. We are the leading company focused specifically on the science, development, and commercialization of acoustic-based technologies for the non-invasive detection of neuropathologies. We are passionate about providing objective diagnostics to enhance therapy and time to treatment for patients suffering from ischemic strokes by providing innovative, clinically proven and economically effective diagnostic solutions for physicians and health care providers.

Project AES101 develops the patented technology that can stimulate the body’s stem cells to regenerate tissues and restore youthful functions. Histogen’s main product application is HSXXX, which is a soluble preparation in clinical development and can be used for hair regrowth injections.

Project AES102 is developed by Korean biopharmaceutical company focused on the discovery, development and commercialization of innovative global therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers. The research efforts are focused on the development of therapeutics inhibiting endothelial dysfunction by tackling multiple mediators including VEGF, Ang-2, bradykinin and so on and maintain vascular homeostasis which is one of the most essential elements in controlling diseases and aging.

Project AES103 has developed a proprietary next-generation AI platform for big biomedical data analysis to discover therapeutics targeting aging. Primary indication: Accelerated aging after chemotherapy/cancer supportive care. Follow-up indications: metabolic syndrome (including NAEFL/NASH); regeneration; rejuvenation; neurogenesis/neuroplasticity; other “hallmarks of aging”. Facts about the company: Top-notch AI investors with exits to Google and Facebook; outstanding lifespan extension and rejuvenation in aged mice (collaboration with B. Kennedy from NUS (ex CEO of the Buck Institute of Aging); collaborations with researchers from Harvard, MIT, Roswell Park Cancer Center.